RE:RE:#ASCO22 Annual Meeting - June 3-7, 2022So funny.
In their 2018 animal models (
mice), they only obtained tumor
regressions in mice. Not even tumor destructions!
And they have to discriminate among patients (anti-PD-1), so their pool of patients is much narrower (3-4x, or about only 25% of the elegible patients) than would be our PDT/PDC technology.
Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1 However, the combination of anti-PD-1 and SAR439459 led to tumor regression in the majority of tumor-bearing mice.
These results provide the rationale for combining TGF-β neutralization with checkpoint inhibitors, specifically anti-PD1, for the treatment of human cancers. _________________________________
ScienceFirst - (5/26/2022 8:04:46 PM) RE:#ASCO22 Annual Meeting - June 3-7, 2022 Another big pharma that we could compare against their innovative oncology pipeline, to see where we stand and what they mean about "innovation":
May 17, 2022: SANOFI Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting Safety and efficacy data for SAR439459, a transforming growth factor beta (TGF-β) inhibitor*
Abstract 2524: Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors